# Corcept Therapeutics Incorporated

Type: Company (CORT)

Source: Finance Intelligence Brief — https://getfinancebrief.com/entity/corcept-therapeutics-incorporated
Canonical HTML page: https://getfinancebrief.com/entity/corcept-therapeutics-incorporated

## Timeline

- **2026-02-23**: Lawsuit Announced — Rosen Law Firm announces the filing of the class action lawsuit and lead plaintiff opportunity.
- **2026-02-20**: Teva Legal Victory — Teva Pharmaceutical Industries wins an appeals court ruling over generic versions of Corcept's Korlym.
- **2025-12-30**: Class Period Ends — The cutoff date for the class action, often coinciding with a corrective disclosure.
- **2024-10-31**: Class Period Begins — The start date for the alleged period of securities fraud and misleading statements.

## Recent coverage (1 stories)

### Corcept Therapeutics Faces Securities Fraud Suit Following Class Period Volatility
2026-02-24 12:34:03 · Sentiment: Neutral · Impact: 5/10 · Sources: 10

Corcept Therapeutics (NASDAQ: CORT) is the target of a class action lawsuit alleging securities fraud during a critical 14-month period of operational and legal shifts. The Rosen Law Firm is seeking lead plaintiffs for a class period that concluded in late 2025, amid intensifying pressure on the company's core product patents.
Full story: https://getfinancebrief.com/story/corcept-therapeutics-securities-fraud-lawsuit-2026

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getfinancebrief.com/guides/methodology for the full editorial methodology.